Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark.
Antimicrob Agents Chemother. 2012 May;56(5):2435-42. doi: 10.1128/AAC.06369-11. Epub 2012 Feb 21.
We recently observed that the micafungin MICs for some Candida glabrata fks hot spot mutant isolates are less elevated than those for the other echinocandins, suggesting that the efficacy of micafungin may be differentially dependent on such mutations. Three clinical C. glabrata isolates with or without (S3) fks hot spot mutations R83 (Fks2p-S663F) and RR24 (Fks1p-S629P) and low, medium, and high echinocandin MICs, respectively, were evaluated to assess the in vivo efficacy in an immunocompetent mouse model using three doses of each echinocandin. Drug concentrations were determined in plasma and kidneys by high-performance liquid chromatography (HPLC). A pharmacokinetic-pharmacodynamic mathematical model was used to define the area under the concentration-time curve (AUC) that produced half- and near-maximal activity. Micafungin was equally efficacious against the S3 and R83 isolates. The estimates for the AUCs of each echinocandin that induced half-maximal effect (E(50)s) were 194.2 and 53.99 mg · h/liter, respectively. In contrast, the maximum effect (E(max)) for caspofungin was higher against S3 than R83, but the estimates for E(50) were similar (187.1 and 203.5 mg · h/liter, respectively). Anidulafungin failed to induce a ≥1-log reduction for any of the isolates (AUC range, 139 to 557 mg · h/liter). None of the echinocandins were efficacious in mice challenged with the RR24 isolate despite lower virulence (reduced maximal growth, prolonged lag phase, and lower kidney burden). The AUC associated with half-maximal effect was higher than the average human exposure for all drug-dose-bug combinations except micafungin and the R83 isolate. In conclusion, differences in micafungin MICs are associated with differential antifungal activities in the animal model. This study may have implications for clinical practice and echinocandin breakpoint determination, and further studies are warranted.
我们最近观察到,一些光滑念珠菌 fks 热点突变株的米卡芬净 MIC 比其他棘白菌素的 MIC 低,这表明米卡芬净的疗效可能依赖于这些突变。我们评估了三个临床分离株光滑念珠菌,它们分别带有或不带有 fks 热点突变 S3 上的 R83(Fks2p-S663F)和 RR24(Fks1p-S629P),并分别具有低、中、高棘白菌素 MIC,使用三种剂量的每种棘白菌素,在免疫功能正常的小鼠模型中评估体内疗效。通过高效液相色谱法(HPLC)在血浆和肾脏中测定药物浓度。使用药代动力学-药效学数学模型来定义产生半最大和接近最大活性的浓度-时间曲线下面积(AUC)。米卡芬净对 S3 和 R83 分离株的疗效相同。每种棘白菌素诱导半最大效应(E(50))的 AUC 估计值分别为 194.2 和 53.99 mg·h/L。相比之下,卡泊芬净对 S3 的最大效应(E(max))高于 R83,但 E(50)的估计值相似(分别为 187.1 和 203.5 mg·h/L)。阿尼芬净对任何分离株都未能诱导≥1 对数减少(AUC 范围为 139 至 557 mg·h/L)。尽管 RR24 分离株的毒力较低(最大生长减少,迟滞期延长,肾脏负荷降低),但在接受 RR24 分离株挑战的小鼠中,所有棘白菌素均无效。除米卡芬净和 R83 分离株外,与半最大效应相关的 AUC 均高于所有药物剂量-细菌组合的平均人体暴露量。总之,米卡芬净 MIC 的差异与动物模型中不同的抗真菌活性有关。这项研究可能对临床实践和棘白菌素折点确定具有影响,需要进一步研究。